KR20240021211A - Klk2-gpi 융합 단백질에 대한 핵산 코딩, 재조합 세포 및 이의 용도 - Google Patents

Klk2-gpi 융합 단백질에 대한 핵산 코딩, 재조합 세포 및 이의 용도 Download PDF

Info

Publication number
KR20240021211A
KR20240021211A KR1020247000497A KR20247000497A KR20240021211A KR 20240021211 A KR20240021211 A KR 20240021211A KR 1020247000497 A KR1020247000497 A KR 1020247000497A KR 20247000497 A KR20247000497 A KR 20247000497A KR 20240021211 A KR20240021211 A KR 20240021211A
Authority
KR
South Korea
Prior art keywords
kallikrein
sequence
cells
gpi
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247000497A
Other languages
English (en)
Korean (ko)
Inventor
스튜어트 엘. 에마누엘
토마스 제이. 룻코스키
Original Assignee
얀센 바이오테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 바이오테크 인코포레이티드 filed Critical 얀센 바이오테크 인코포레이티드
Publication of KR20240021211A publication Critical patent/KR20240021211A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21035—Tissue kallikrein (3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C07K2319/912—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation containing a GPI (phosphatidyl-inositol glycane) anchor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020247000497A 2021-06-10 2022-06-08 Klk2-gpi 융합 단백질에 대한 핵산 코딩, 재조합 세포 및 이의 용도 Pending KR20240021211A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163209019P 2021-06-10 2021-06-10
US63/209,019 2021-06-10
PCT/IB2022/055355 WO2022259190A1 (en) 2021-06-10 2022-06-08 Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof

Publications (1)

Publication Number Publication Date
KR20240021211A true KR20240021211A (ko) 2024-02-16

Family

ID=82358484

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000497A Pending KR20240021211A (ko) 2021-06-10 2022-06-08 Klk2-gpi 융합 단백질에 대한 핵산 코딩, 재조합 세포 및 이의 용도

Country Status (11)

Country Link
US (1) US20220403397A1 (https=)
EP (1) EP4352217A1 (https=)
JP (1) JP2024520790A (https=)
KR (1) KR20240021211A (https=)
CN (1) CN117480253A (https=)
AU (1) AU2022291273A1 (https=)
BR (1) BR112023025616A2 (https=)
CA (1) CA3222756A1 (https=)
IL (1) IL309179A (https=)
MX (1) MX2023014793A (https=)
WO (1) WO2022259190A1 (https=)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6113917A (en) * 1995-04-25 2000-09-05 Rmf Dictagene S.A. Modified polypeptides for enhanced immunogenicity
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
DK1716233T3 (da) * 2004-01-30 2009-10-26 Maxygen Holdings Ltd Reguleret stopkodongennemlæsning
AU2005295421A1 (en) * 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble Zcytor21, anti-Zcytor21 antibodies and binding partners and methods of using in inflammation
EP2315846A4 (en) * 2008-08-05 2011-11-30 Univ Rochester PSA AND KLK2 AS THERAPEUTIC TARGET MOLECULES AND PSA AND KLK2-INHIBITABLE MOLECULES
WO2012068317A2 (en) * 2010-11-16 2012-05-24 Excelimmune, Inc. Methods for producing recombinant proteins
JP7235436B2 (ja) * 2014-11-10 2023-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 細胞の表面上にポリペプチドを発現させるための組成物および方法
AU2020322221A1 (en) * 2019-07-26 2022-03-24 Janssen Biotech, Inc. Anti-hK2 chimeric antigen receptor (CAR)

Also Published As

Publication number Publication date
EP4352217A1 (en) 2024-04-17
CN117480253A (zh) 2024-01-30
MX2023014793A (es) 2024-03-25
US20220403397A1 (en) 2022-12-22
AU2022291273A1 (en) 2024-01-25
BR112023025616A2 (pt) 2024-02-27
WO2022259190A1 (en) 2022-12-15
CA3222756A1 (en) 2022-12-15
JP2024520790A (ja) 2024-05-24
IL309179A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
AU2022203195B2 (en) Mnd promoter chimeric antigen receptors
KR102530118B1 (ko) 유도 ｄｎａ 결합 단백질 및 게놈 교란 도구 및 이의 적용
KR20210056329A (ko) 신규 cas12b 효소 및 시스템
KR20240021218A (ko) 신규 유형 v rna 프로그래밍가능 엔도뉴클레아제 시스템
KR20230010231A (ko) 생체내 형질도입을 위한 벡터 및 방법
JP2022543589A (ja) Ｋｌｆ誘導心筋再生
CN113355323B (zh) 人源化ace2基因改造小鼠模型的制备方法及应用
CN116887854A (zh) Omni-103 crispr核酸酶
WO2008144052A2 (en) Bioluminescent imaging of stem cells
CN110087676A (zh) 用于治疗癌症的包含表达nfatc4的细胞的分泌性胞外囊泡的组合物
CN112980800A (zh) Car-t细胞、其构建方法及其应用
CN113355325B (zh) 人源化ace2基因改造小鼠胚胎干细胞模型制备方法及应用
KR20230142740A (ko) Omni-103 crispr 뉴클레아제
KR102624831B1 (ko) 근육 특이적 pck1 과발현 형질전환 개 생산
KR20240021211A (ko) Klk2-gpi 융합 단백질에 대한 핵산 코딩, 재조합 세포 및 이의 용도
CN101760475B (zh) 重组逆转录病毒载体
CN111727244B (zh) 循环肿瘤细胞的通用检测探针
CN107384921B (zh) miR216a用于抑制骨肉瘤细胞的增殖、侵袭和迁移
CN113736741A (zh) 一种用于测定特立帕肽生物学活性的克隆化细胞株
KR102468650B1 (ko) T7 RNA 중합효소 및 mRNA 캡핑 효소를 유도 발현하는 재조합 벡터 및 이의 용도
HK40102227A (zh) Omni-103 crispr核酸酶
CN115044617B (zh) Car t细胞的制备方法、car t细胞及其应用
KR20180027383A (ko) 목적 단백질의 위치 특이적 변형이 시공간적으로 조절되는 마우스, 이의 제조방법 및 그 용도
JP2003024078A (ja) 三量体型ｇ蛋白質の活性モニター分子
HK40038630A (en) Probe for universal detection of circulating tumor cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240105

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250605

Comment text: Request for Examination of Application